** HK-listed shares of Laekna 2105.HK soar 37.2% to HK$14.54, highest since Jan. 11
** Stock set for biggest one-day pct rise since April 15
** Chinese biotech firm enters into agreement with Eli Lilly LLY.N to accelerate global clinical development of LAE102, used to treat obesity
** Under the deal, Lilly will fund and execute LAE102's phase I study in the U.S., while Laekna will retain the drug's global rights
** Hong Kong's healthcare index .HSCIH up 2.8%, while Hang Seng Index .HSI slips 0.1%
** Stock trims YTD losses to 32.3%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。